SV investment has resulted in the approval of 24 novel therapeutics
SV News
- 23 June 2020Portfolio NewsSV Health Investors notes Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics
23 June 2020Portfolio NewsBicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board
23 June 2020Portfolio NewsAlchemab Therapeutics among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK- 22 June 2020Portfolio NewsDeciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
17 June 2020Portfolio NewsXilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors- 11 June 2020Portfolio NewsX4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer
- 8 June 2020Portfolio NewsDeciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
3 June 2020Portfolio NewsErvaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR‐based cancer immunotherapies- 29 May 2020Portfolio NewsDeciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCKTM (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program
- 21 May 2020Portfolio NewsSutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
- 15 May 2020Portfolio NewsFDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
13 May 2020Portfolio NewsAVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
